Leerink Partnrs Has Pessimistic View of INSP FY2024 Earnings

Inspire Medical Systems, Inc. (NYSE:INSP) – Leerink Partnrs decreased their FY2024 EPS estimates for Inspire Medical Systems in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of $1.37 for the year, down from their prior forecast of $1.38. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $1.33 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ Q2 2025 earnings at $0.40 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $1.73 EPS and FY2026 earnings at $2.62 EPS.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, November 4th. The company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.54. The business had revenue of $203.20 million during the quarter, compared to analyst estimates of $197.59 million. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. The business’s revenue was up 32.6% on a year-over-year basis. During the same period last year, the business earned ($0.29) EPS.

INSP has been the subject of a number of other reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $260.00 price target on shares of Inspire Medical Systems in a report on Tuesday, November 5th. Wells Fargo & Company raised their price target on shares of Inspire Medical Systems from $187.00 to $198.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. KeyCorp reduced their price objective on shares of Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Bank of America upgraded shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and increased their price objective for the company from $220.00 to $255.00 in a research note on Wednesday, November 20th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $200.00 price objective (up from $170.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $233.58.

Inspire Medical Systems Trading Up 2.5 %

INSP opened at $193.85 on Wednesday. The company has a fifty day simple moving average of $198.72 and a 200 day simple moving average of $175.85. The firm has a market cap of $5.81 billion, a price-to-earnings ratio of 181.17 and a beta of 1.36. Inspire Medical Systems has a twelve month low of $123.00 and a twelve month high of $257.40.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. True Wealth Design LLC acquired a new stake in shares of Inspire Medical Systems during the third quarter worth approximately $30,000. Farther Finance Advisors LLC lifted its stake in Inspire Medical Systems by 1,158.3% in the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock valued at $32,000 after acquiring an additional 139 shares during the last quarter. GAMMA Investing LLC lifted its stake in Inspire Medical Systems by 559.3% in the third quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock valued at $38,000 after acquiring an additional 151 shares during the last quarter. SouthState Corp bought a new stake in Inspire Medical Systems in the second quarter worth approximately $27,000. Finally, Signaturefd LLC grew its position in Inspire Medical Systems by 45.9% in the third quarter. Signaturefd LLC now owns 270 shares of the company’s stock worth $57,000 after acquiring an additional 85 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 800 shares of Inspire Medical Systems stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total value of $176,000.00. Following the transaction, the director now directly owns 23,140 shares of the company’s stock, valued at $5,090,800. This trade represents a 3.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.10% of the stock is owned by corporate insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.